122 related articles for article (PubMed ID: 18097008)
1. Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
Mariotti J; Foley J; Jung U; Borenstein T; Kantardzic N; Han S; Hanson JT; Wong E; Buxhoeveden N; Trepel JB; Fojo AT; Telford W; Fowler DH
J Immunol; 2008 Jan; 180(1):89-105. PubMed ID: 18097008
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
3. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism.
Foley JE; Jung U; Miera A; Borenstein T; Mariotti J; Eckhaus M; Bierer BE; Fowler DH
J Immunol; 2005 Nov; 175(9):5732-43. PubMed ID: 16237064
[TBL] [Abstract][Full Text] [Related]
5. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin-resistant effector T-cell therapy.
Fowler DH
Immunol Rev; 2014 Jan; 257(1):210-25. PubMed ID: 24329799
[TBL] [Abstract][Full Text] [Related]
7. Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.
Fowler DH; Bishop MR; Gress RE
Semin Oncol; 2004 Feb; 31(1):56-67. PubMed ID: 14970938
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Fowler DH; Mossoba ME; Steinberg SM; Halverson DC; Stroncek D; Khuu HM; Hakim FT; Castiello L; Sabatino M; Leitman SF; Mariotti J; Gea-Banacloche JC; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Rowley S; Goy A; Donato M; Korngold R; Pecora A; Levine BL; June CH; Gress RE; Bishop MR
Blood; 2013 Apr; 121(15):2864-74. PubMed ID: 23426943
[TBL] [Abstract][Full Text] [Related]
9. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.
Mariotti J; Foley J; Ryan K; Buxhoeveden N; Kapoor V; Amarnath S; Fowler DH
Blood; 2008 Dec; 112(12):4765-75. PubMed ID: 18625883
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Fowler DH; Odom J; Steinberg SM; Chow CK; Foley J; Kogan Y; Hou J; Gea-Banacloche J; Sportes C; Pavletic S; Leitman S; Read EJ; Carter C; Kolstad A; Fox R; Beatty GL; Vonderheide RH; Levine BL; June CH; Gress RE; Bishop MR
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1150-60. PubMed ID: 17085308
[TBL] [Abstract][Full Text] [Related]
11. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH.
Haeryfar SM; Lan Z; Leon-Ponte M; Duffy KR; Ge W; Liu W; Mele T; Garcia B; Wang H
Transplantation; 2008 Aug; 86(3):460-8. PubMed ID: 18698251
[TBL] [Abstract][Full Text] [Related]
12. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
13. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.
Jung U; Foley JE; Erdmann AA; Eckhaus MA; Fowler DH
Blood; 2003 Nov; 102(9):3439-46. PubMed ID: 12855580
[TBL] [Abstract][Full Text] [Related]
14. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
15. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting.
Wang H; Hosiawa KA; Min W; Yang J; Zhang X; Garcia B; Ichim TE; Zhou D; Lian D; Kelvin DJ; Zhong R
J Immunol; 2003 Oct; 171(7):3823-36. PubMed ID: 14500684
[TBL] [Abstract][Full Text] [Related]
16. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection.
Fowler DH; Gress RE
Vox Sang; 1998; 74 Suppl 2():331-40. PubMed ID: 9704464
[TBL] [Abstract][Full Text] [Related]
18. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.
Lim DG; Koo SK; Park YH; Kim Y; Kim HM; Park CS; Kim SC; Han DJ
Transplantation; 2010 Apr; 89(8):928-36. PubMed ID: 20305583
[TBL] [Abstract][Full Text] [Related]
20. Non-host-reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection.
Fowler DH; Whitfield B; Livingston M; Chrobak P; Gress RE
Blood; 1998 Jun; 91(11):4045-50. PubMed ID: 9596648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
